Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 3Triple Negative Breast Neoplasms 2Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia, Myeloid, Acute 1Hodgkin Disease 1Hematopoietic and Lymphatic System Neoplasm 1Graft vs Host Disease 1Cholangiocarcinoma 1Bronchiolitis Obliterans Syndrome 1

Interventions

Cyclophosphamide 7Mycophenolic Acid 6Tacrolimus 5Busulfan 4ruxolitinib 3fludarabine phosphate 3fludarabine 3Whole-Body Irradiation 3Melphalan 3Thiotepa 2Specimen Handling 2Sirolimus 2Cyclosporine 2belumosudil 1axatilimab 1Stem Cell Transplantation 1Peripheral Blood Stem Cell Transplantation 1Panobinostat 1Methotrexate 1Low-Level Light Therapy 1Leukocyte Count 1Hematopoietic Stem Cell Transplantation 1Etoposide 1Emapalumab 1Clofarabine 1Clinical Trials, Phase I as Topic 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Graft vs Host Disease × axatilimab × 90 days × Clear all
NCT04710576 2026-03-16

AGAVE-201

Syndax Pharmaceuticals

Phase 2 Active not recruiting
241 enrolled 11 charts 1 FDA

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡